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Introduction Pneumococcal disease causes considerable morbidity and mortality, 
including among adults. Adult pneumococcal vaccines help to prevent these 
burdens, yet, they are underutilized. Our objective is to systematically collect 
and summarize the available evidence on the potential factors that lead to 
pneumococcal vaccination acceptance among of adult community. 
Methods A systematic literature search was conducted involving studies published 
from January 1999 to December 2015. The studies were identified by 
searching electronic resources (PubMed/MEDLINE and Pro Quest database) 
and manual searches of references. The keywords “vaccine/ immunization”, 
“uptake/ coverage”, “determinant/ factor”, and “Streptococcus pneumoniae/ 
pneumococcus/ pneumococcal” were used. Final studies result and data were 
reviewed by two independent authors. Disagreement was resolved through 
discussion and consensus. 
Results A total of 171 studies were identified, only 17 studies were included in final 
discussion with 10 domains identified in the paper. 7 studies (41%) had 
reported that the provider domain, patients’ perception and 
socio-demographic factor have had the most effect on the pneumococcal 
vaccination acceptance rate. In addition, only 18% (3) of reviewed papers had 
highlighted that socio-economic was a factor influenced the pneumococcal 
vaccination acceptance while 24% (4 studies) were attributed to the comorbid 
domains. 
Conclusions Healthcare provider and patients’ perception about pneumococcal vaccination 
for adult population are significant domains which influence the acceptance 
towards vaccination. Strong recommendations from healthcare provider for 
pneumococcal vaccination would be an important step to increase vaccination 
acceptance among the population. 
Keywords Pneumococcal vaccination - Adult population - Acceptance. 
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INTRODUCTION 
Pneumococcal disease, caused by the common 
bacteria Streptococcus pneumoniae, is associated 
with considerable morbidity and mortality as well 
as considerable health care costs disease. 
Pneumococcal disease is transmitted from person 
to person through close contact via respiratory 
droplets. The symptoms and severity of the disease 
vary depending on the clinical syndrome.1 The 
most serious clinical manifestations of 
pneumococcal disease are pneumonia and invasive 
pneumococcal disease (IPD), which includes 
meningitis and bacteraemia.2 Pneumococcal 
infection is responsible for 30–50% of pneumonia 
cases in children followed by Haemophilus 
influenza type B for 10–30% of cases.3 
Pneumococcal disease is found to be of the main 
cause of mortality and morbidity for children under 
five years of age, mainly in developing nations.4 
Approximately, 1.6 million people 
globally die from the pneumococcal infection every 
year, in which almost 1 million from that figure are 
children under the age of five years. In 2009, 
Indonesia accounted for the sixth rank or 3% of the 
reported pneumococcal cases worldwide.5 It was 
reported that population older than 65 years are 
vulnerable to complications from influenza 
infection and invasive pneumococcal disease.6 All 
adults aged 65 years are at increased risk of 
developing pneumococcal disease, as are persons 
of any age with immunosuppressive conditions (i.e. 
cancer, HIV/AIDS, diabetes, alcoholism, chronic 
diseases of the heart, lung, liver, and kidney, and 
those who smoke cigarettes).7 
The history of pneumococcal vaccination 
began more than 30 years ago in the USA, where 
the 23-valent pneumococcal polysaccharide 
vaccine (PPSV23) was licensed. PPSV23 is 
currently recommended in people aged >65 years 
and in high-risk adults aged 19-64 years.8 
Pneumococcal vaccine that is used for childhood 
pneumococcal vaccination was first recommended 
in the United States in 2000 and was widely used in 
26 countries. Since 2006, 18 out of these 26 
countries have introduced the vaccine including 
Australia, New Zealand, South Korea, and 
countries in Europe, the Americas, and the Middle 
East.9  
The main objective for pneumococcal 
vaccination is to get vaccine coverage more than 90% 
among at-risk populations.10 After the vaccine 
introduction in many of those countries, the regular 
use of this vaccine has led to huge decline of 
invasive pneumococcal disease (IPD).11 In the 
United States, routine use of the 7-valent 
pneumococcal conjugate vaccine (PCV7) in 
children since 2000 has led to waning disease 
incidence in this population, as well as reductions 
in IPD cases among adults due to “herd 
immunity”2. The widespread use of PCV7 in 
children has altered the epidemiology of 
pneumococcal infections, bringing down the 
burden of adult pneumococcal disease. Adults 
presently bear the major burden of serious IPD; 
where about 85% of all IPD cases now occur in 
persons aged >18 years.12 Previous studies have 
found associations between pneumococcal 
vaccination status and patient belief that the 
pneumococcal vaccine is effective and is a good 
idea and that pneumonia is a serious disease for the 
elderly.13 
The Advisory Committee on 
Immunization Practices (ACIP) recommends that 
pneumococcal polysaccharide vaccine be 
administered to people aged ≥ 65 years; 
immunocompetent people aged ≥2 years who are 
at increased risk for illness and death from 
pneumococcal disease because of certain chronic 
medical conditions; people with functional or 
anatomic asplenia; and immunocompromised 
people who are at high risk for infection14. As for 
those people aged ≥ 65 years should be 
administered a second dose of pneumococcal 
vaccine if they received the first dose of vaccine 
≥5 years previously and were aged <65 years at 
that time.14 
The Advisory Committee on 
Immunization Practices developed guidelines in 
1997, recommending all adults ages 65 and older 
receive the vaccine; however, the immunization 
rates among older adults are low.15 In 2014, 
pneumococcal vaccination coverage (23-valent 
pneumococcal polysaccharide vaccine [PPSV23] 
and 13-valent pneumococcal conjugate vaccine 
[PCV13]) among adults aged 19–64 years at high 
risk was 20.3% in the United States16. Meanwhile, 
the coverage was 61.3% among adults aged ≥65 
years, which did not progress from 2013.16 
Pneumococcal vaccination has been 
shown to reduce morbidity, mortality and health 
care costs.17 A safe and effective pneumococcal 
vaccine is available, but underused.18 However, 
there are still few issues hindered more broad-scale 
use of pneumococcal vaccination, including doubts 
about its effectiveness in reducing the incidence of 
community-acquired pneumonia. The incremental 
cost-effectiveness of the vaccine in persons 
immunized against pneumonia and patient 
compliance.19 However, pneumococcal vaccine has 
limited effectiveness against invasive 
pneumococcal disease, especially among 
immunocompromised adults, and PPSV23 
protection is short-lived, with a rapid waning of 
antibody concentrations and with a lack of memory 
B-cell production following immunization.20 
Both physician and patient factors 
contribute to this suboptimal vaccination rate. 
While physicians often miss opportunities to 
vaccinate patients, patients also refuse vaccination. 
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Vaccine refusers have not been targeted for study 
in the past.21 The objectives of this study are to 
understand and identify the potential factors that 
lead to pneumococcal vaccination acceptance 
among of adult community. 
 
METHODOLOGY 
Systematic Literature Review (SLR) was carried 
out on factors and determinants which were 
associated with pneumococcal vaccination intake 
or acceptance, considering key words used in 
combination and referred to vaccine/immunization, 
uptake/coverage, determinant/factor, and 
Streptococcus pneumoniae/ pneumococcus/ 
pneumococcal, with medical subject headings 
(MeSH) and MeSH major topics included in the 
syntax.  
 
Figure 1  Flow Systematic Literature Review (SLR) diagram of the factors of pneumococcal vaccination 
acceptance 
 
The PubMed/MEDLINE online database 
was utilized, as well as the grey literature, and a 
manual search was performed based on the 
references of the articles retrieved. Original 
qualitative and quantitative articles published from 
January 1999 to December 2015 were collected. 
Through standardized database searching, 171 
records were identified. After duplicates were 
removed, 151 records were screened and 126 
records were excluded on the basis of title and 
abstract screening (based on language, study setting, 
methodology, or target population). Finally, among 
25 articles assessed for eligibility, 8 were excluded 
on basis of exclusion criteria and 17 were analysed 
in this study (Figure 1). 
 
RESULT 
There was a total of 17 eligible papers reviewed 
and summarised based on the year of published, 
author and findings (Table 1). Twelve papers were 
qualitative study. The findings were further 
classified into main domains based on the Health 
Belief Model and domains used in other related 
literatures. The domains are: awareness, 
socio-demographic, knowledge, perception, 
provider, socio-economic, social factor and others. 
  
SCREENING 
151 records after removal of duplicates 
ELIGIBILITY 
25 full text articles assessed for 
eligibility 
 
INCLUSION 
Final 17 studies included in the study  
126 records excluded with title and abstract 
screening based on criteria: 
 Language other than English 
 Incomplete articles 
 Published from <1999 
 Population age<18 
 Not focusing on pneumococcal 
vaccination. 
8 records excluded based on criteria: 
 Assessing only vaccination coverage 
 Reporting uptake determinants not 
provided in first person or by parents 
(e.g., health care workers) 
 Reporting association with 
information-seeking and not with 
uptake 
 Reporting no specific indications on 
pneumococcal vaccination. 
IDENTIFICATION 
171 records identified through PubMed 
and Pro Quest database searching 
20 duplicated records were removed  
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Table 1 Summary of study characteristic and findings for comparison 
 
Year Author Geographical setting/ 
Target population 
Significant Determinant Domain Classification 
1999 Kyaw et al. 
  
Birmingham, 
United Kingdom / 
 
Patients admitted at a large 
teaching hospital 
 Unaware vaccine existed 
 General Practitioner(GP) had 
not recommend the vaccine 
 GP recommended but patient 
refused 
 Fear of adverse reaction 
 Vaccine contraindicated due to 
current therapy 
 Could not be bothered 
 Did not think it would work 
 Awareness 
 Provider 
 
 Perception 
 
 Side effect 
 Side effect 
 
 Attitude 
 Perception 
2001 Wahid et al. 
 
Middlesbrough, 
Gateshead and Newcastle, 
United Kingdom / 
 
Out-patient diabetic 
patients 
 Not aware of need 
 Previous side effects 
 Believed not effective 
 No time 
 Never offered 
 Awareness 
 Side-effect 
 Perception 
 Attitude 
 Provider 
2001 
 
Opstelten et al. 
 
Amersfoort, Netherlands / 
Patients from 2 solo and 2 
group General 
Practitioners 
 General Practitioner(GP) did 
not recommend the vaccine 
 Expected local side effects 
from pneumococcal 
vaccination 
 Provider 
 
 Side effect 
2003 Egede & 
Zheng 
US National Health 
Interview Survey / 
 
Individuals aged >18 years 
old with at least one 
chronic medical condition 
 Age > 65  
 Race; Non-Hispanic White 
 Income, $<20 000 
 Employed 
 Health care coverage 
 Access to care 
 One Comorbid conditions 
 Socio-demo 
 Socio-demo 
 Socio-econ 
 Socio-econ 
 Socio-econ 
 Provider 
 Co-morbid 
2003 William et al. 
 
USA  Unnecessary 
 Doctor did not recommend 
 Did not think of missed 
 Do not prevent 
pneumococcal disease 
 Not at risk of developing 
pneumococcal 
 Fear of shot/needles   
 Perception 
 Provider 
 Perception 
 Knowledge 
 
 Perception 
 
 Perception 
2004 Nowalk et al.  Pittsburgh, USA / 
Patients from inner-city 
health centers 
 Attitude 
 Social influence 
 Perceived consequences 
 Attitude 
 Social 
 Side effect 
2005 Singleton et al. Atlanta, Georgia / 
 
Adults aged >65 years 
community 
 Concerned about side effects 
 Do not think the vaccine 
works 
 Do not think the need for 
vaccination 
 Allergic to the vaccine 
 Side effect 
 Perception 
 
 Attitude 
 
 Side effect 
2006 
 
Nowalk et al. Pittsburgh, USA /  
 
Adults aged at least 50 
years old 
 
 Female; OR 3.79 (1.47,9.74) 
 Smoking status-Never smoked 
OR; 10.67 (1.67,68.28) 
 Frequency of visits to 
physician – 3-4 times per year 
OR; 8.77 (2.36 – 32.62)  
 Socio-demo 
 Social 
 
 Awareness 
2006 Daniels et al. California, USA / 
 
Patient attending general 
 Vaccine is unnecessary 
 Fearing shots in general 
 Fearing vaccine-induced 
 Perception 
 Perception 
 Perception 
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medicine clinic illness 
 Wanting more information 
regarding the vaccine 
 
 Knowledge 
 
2006 Vila-Corcoles 
et al. 
Catalonia, Spain / 
 
Individuals aged more 
than 65 years old  
 Age > 75 
 Chronic lung disease  
 Diabetes mellitus 
 Active neoplasia 
 Immunocompromised   
 Chronic heart disease  
 Chronic nephropathy 
 Obesity  
 Socio-demographic 
 
 
 
 Co-morbid 
2008 Merrick  et al.  The primary data source 
from nationally 
representative 2003 
Medicare Current 
Beneficiary Survey 
(MCBS) in US 
 Age ≥81; OR 2.16 (1.88,2.47) 
 Race-Black; OR 0.62 
(0.51,0.74) 
 College degree; OR 
1.23(1.04,1.46)  
 Income >$40,000; 
  OR 1.28 (1.11,1.48) 
 Relative health risk; 
OR 1.10 (1.05,1.14) 
 Private supplemental 
insurance; 
OR 1.25 (1.09,1.44) 
 Non-drinker; OR 0.94 
(0.83,1.07) 
 Socio-demographic 
 Socio-demographic 
 
 Socio-economic 
 
 Socio-economic 
 
 Co-morbidity 
 
 Socio-economic 
 
 
 Social 
2008 Hausmann et 
al.  
Using ‘Behavioral Risk 
Factor Surveillance 
System (BRFSS) among 
adults in USA 
 Perceived positive racial 
discrimination; 
OR 1.47 (1.20,1.80)  
 Social 
2008 Ridda et al. 
 
Sydney, Australia / 
 
Patients aged 60 years and 
older who are admitted to 
selected wards in a tertiary 
referral hospital  
 More positive attitude to 
vaccination  
 More positive perception to 
vaccination. 
 Older patients tend to be 
more likely to receive either 
both or any one of the 
vaccine. 
 More correct knowledge on 
vaccination 
 Attitude 
 
 Perception 
 
 Socio-demo 
 
 
 
 Knowledge 
2010 Jones et al. 
 
USA / 
 
Adults age ≥65  
years of age between 1989 
and 1993 
 Racial variation in the receipt 
of influenza vaccine. 
 Lack of awareness of the 
benefits 
 Higher income 
 Lack of contact with 
health-care providers or 
missed opportunities to 
vaccinate during contact. 
 Socio-demo 
 
 Awareness 
 
 Socio-econ 
 Provider 
2010 Daniels et al. 
 
California, USA  Increasing age 
 Female  
 Being a former smoker 
 Having a check-up in the past 
year 
 Having diagnosed with heart 
disease 
 Socio-demo 
 Socio-demo 
 Social 
 Awareness 
 
 Co-morbid 
2015 Eilers et al. 
 
Netherlands / 
 
Age >50 years old from 
 Healthy aging 
 Usefulness of vaccination in 
older age 
 Social 
 Awareness 
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sheltered housing 
institutions, care homes, 
and residential 
groups across the 
Netherlands 
 Risk of getting an infectious 
disease 
 Vaccine characteristics 
 Severity of the disease 
 The experiences of previous 
vaccinations 
 The influence of healthcare 
workers and other people 
 The need for information. 
 Perception 
 
 Side-effect 
 Perception 
 Perception 
 
 Provider 
 
 Knowledge 
2015 Loubet et al. 
  
France /  
 
Adults > 18 years old who 
are immunocompromised 
patients 
 Favourable attitude towards 
vaccination in general  
aOR 4.20 (3.20-5.51) 
 High global knowledge 
aOR 2.21 (1.55-3.15) 
 Attitude 
 
 
 Knowledge 
 
Out of 17 studies, 7 studies (41%) had 
reported that the provider domain, patients’ 
perception and socio-demographic factor had the 
most effect on the pneumococcal vaccination 
acceptance rate. In addition, only 18% of the 
reviewed papers had highlighted that 
socio-economic factor had influenced the 
pneumococcal vaccination acceptance while 24% 
were attributed to the comorbid domains (Table 2). 
 
Table 2 Distribution of study factors in pneumococcal vaccination acceptance and refusal 
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Awareness x x      x      x x x  6 
Side effect x x x   x x         x  6 
Knowledge     x    x    x   x x 5 
Perception X X   X  x  x    X   X  7 
Provider X X x X x 
 
        X  X  7 
Social      X  X   X x   X X  6 
Socio-demogr
aphic factor 
   X    x  X X  X X X   7 
Socio-econom
ic status 
   X       x   x    3 
Co-morbid    x      x X    x   4 
Attitude x x    x X      x    x 6 
 
DISCUSSION 
Pneumococcal infections, including pneumonia and 
invasive disease such as bacteremia and meningitis, 
are important sources of morbidity and mortality in 
infants and young children, older adults (≥65 years 
of age), and persons with conditions that affect their 
ability to produce antibody. Patients with chronic 
lung disease are at increased risk for pneumococcal 
pneumonia, and patients with conditions such as 
heart failure are more likely to have adverse 
outcomes if pneumonia occurs. Asplenic patient 
greatly increases the risk for overwhelming 
pneumococcal sepsis, and cerebrospinal fluid leak 
or a cochlear implant greatly increases the risk for 
meningitis. Pneumococcal vaccination is 
recommended for all children and for adults who 
have a condition that places them at increased risk 
for developing pneumonia or invasive 
pneumococcal disease or for having a serious 
outcome should pneumonia develop.7 
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The highest incidence of invasive 
pneumococcal disease occurs in children <5 years of 
age, persons who have conditions that compromise 
antibody responses (eg, solid organ transplantation, 
multiple myeloma, HIV infection), and those ≥65 
years of age. The highest mortality rates occur in 
individuals aged more than 65 years of age, 
especially in those who have significant 
comorbidities.22 Preventing pneumococcal disease 
in older adults and those with certain underlying 
conditions is an important goal given the burden of 
disease and associated morbidity and mortality in 
these populations. The development of 
pneumococcal conjugate vaccines represented a 
major advance; the universal use of such vaccines in 
infants has led to dramatic reductions in the 
incidence of pneumococcal disease. This decline is 
seen both among children who are vaccinated and, 
because the vaccine effectively eradicates nasal 
colonization, also among older, unvaccinated 
children and adults.22  
However, several factors are believed to 
influence the acceptance of pneumococcal 
vaccination. With the vaccine efficacy, up to 60% 
for all serotype (Cochrane systematic review), this 
vaccine is not widely promoted to the populations.23 
Acceptance and refusal factors of pneumococcal 
vaccination can be divided into multifactorial of 
person, provider and policy factors.24 Studies have 
found that the reason most people do not take this 
vaccine is either due to poor recommendation or 
the vaccination was not provided.25,26 In some 
cases, vaccination was even not recommended by 
the general practitioner.25,27  
One of the main factors that influence the 
acceptance of vaccination was the perception of the 
individual. Among the good perception towards 
acceptance of pneumococcal vaccination was that 
the patient believed the vaccination may prevent 
them against invasive pneumococcal disease24 
while most of refusal perception towards 
pneumococcal vaccination stated that the vaccine 
may produce adverse side-effect and not effective24, 
25 and vaccine is believed to be contradicted with 
current therapy.26 Negative attitudes and 
misconceptions about vaccination and because of 
fear of shots or vaccine-related illness may be 
related to refusal towards vaccination in low 
education population.25 
 
 
 
Figure 2 Descriptive analysis of acceptance of pneumococcal vaccination 
 
History of taking influenza vaccination is 
the most significant factor contributed to 
acceptance of pneumococcal vaccination (Figure 2). 
Studies showed that the history of taking flu 
vaccination may give high odds of taking 
pneumococcal vaccination with OR 54.8 and 12.8 
respectively. This was because that most of the 
patient believed that they will be protected after 
taking the vaccination.28,29 Other sociodemographic 
factor such as gender had showed female were 
more likely to accept the pneumococcal 
vaccination comparing to male30 while other 
studies had not given the significant difference 
between the gender towards vaccine 
acceptance.28,31 Other studies showed that those 
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who are more than 65 years contributed to 
significant acceptance factor.29,30  
 
RECOMMENDATION 
Among some recommendations that could be 
implemented in order to achieve high coverage of 
pneumococcal vaccination should include 
increasing awareness among high risk groups and 
providing education on the benefits of 
pneumococcal through social media, such as 
Facebook, Twitter or blogs. The healthcare 
provider can create their own social media accounts 
to offset that content with information favoring 
immunization. 
Physician recommendation is the most 
important factor influencing a patient's decision to 
be immunized, and, in fact, most patients won't get 
vaccinated without a physician recommendation. 
Trust develops when patients identify both 
competence and caring in their physician. A 
trusting relationship is also necessary to effectively 
communicate the benefits of these interventions 
and address barriers to vaccinations. One way to 
make sure patients receive the recommendation is 
to create a system with the team, making 
vaccination a front-end priority, rather than an 
afterthought, and appropriately delegating authority. 
Hence, pphysician’s' attitudes and practices are 
important for this matter.  
Meanwhile, elderly patients may also 
remember what life was like in their community 
when measles, mumps, and polio were endemic, 
before vaccines became available. Sharing 
experience by combining their experience with our 
medical advice can be a useful way to emphasize 
the importance of vaccinations. 
 
STRENGTH AND LIMITATIONS 
Strengths of this systematic review include the 
large number of articles screened to get different 
racial, ethnic, age, and multicentre studies with 
different geographical area that may represent 
whole population as general. The review had also 
covered a long period to consider all studies from 
the year 1999 till 2015. However, there were 
several limitations of the review such as this review 
had only considered free open access published 
articles and accessible search engines or online 
databases. 
 
CONCLUSION 
In conclusion, healthcare provider and patients’ 
perception on pneumococcal vaccination for adult 
population are significant domains which influence 
the acceptance towards vaccination. Strong 
recommendations from healthcare provider for 
pneumococcal vaccination would be an important 
step to increase vaccination acceptance among the 
population. 
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